Adenosine A2A receptor antagonist istradefylline (KW‐6002) reduces “off” time in Parkinson's disease: A double‐blind, randomized, multicenter clinical trial (6002‐US‐005)
Identifieur interne : 000E73 ( Main/Exploration ); précédent : 000E72; suivant : 000E74Adenosine A2A receptor antagonist istradefylline (KW‐6002) reduces “off” time in Parkinson's disease: A double‐blind, randomized, multicenter clinical trial (6002‐US‐005)
Auteurs : Peter A. Lewitt [États-Unis] ; M. Guttman [Canada] ; James W. Tetrud [États-Unis] ; Paul J. Tuite [États-Unis] ; Akihisa Mori [Japon] ; Philip Chaikin [États-Unis] ; Neil M. Sussman [États-Unis]Source :
- Annals of Neurology [ 0364-5134 ] ; 2008-03.
Abstract
Objective: Based on new understanding of nondopaminergic pathways involved in Parkinson's disease (PD) pathophysiology, a selective adenosine A2A receptor antagonist, istradefylline, shows promise for the treatment of PD. Methods: Istradefylline (40mg/day) was studied in levodopa‐treated PD subjects experiencing prominent wearing‐off motor fluctuations. At 23 North American sites, 196 subjects were randomized in a double‐blind, 12‐week outpatient clinical trial of istradefylline (114 completing the trial) or placebo (58 completing the trial). The primary efficacy measure was change from baseline to end point in the percentage of daily awake “off” time, recorded by subjects using a patient PD diary. Secondary end points evaluated “on” time (including “on time with dyskinesia”), the Unified Parkinson's Disease Rating Scale, and a Clinical Global Impression–Improvement of Illness score. Clinical laboratory, electrocardiograms, vital signs, and adverse event monitoring comprised the safety monitoring. Results: After randomization, approximately 88% of subjects completed the double‐blind period. Compared with baseline, the decrease of daily awake “off” time for istradefylline was a mean (± standard deviation) of −10.8 ± 16.6% (95% confidence interval, −13.46 to −7.52) and for placebo, −4.0 ± 15.7% (95% confidence interval, −7.73–0.31; p = 0.007 using two‐way analysis of variance). This effect corresponded to changes from baseline in total daily awake “off” time of −1.8 ± 2.8 hours for istradefylline and −0.6 ± 2.7 hours for placebo (p = 0.005). Treatment‐emergent adverse effects with istradefylline were generally mild. Interpretation: Istradefylline was safe, well tolerated, and offered a clinically meaningful reduction in “off” time without increased troublesome dyskinesia. Ann Neurol 2008
Url:
DOI: 10.1002/ana.21315
Affiliations:
- Canada, Japon, États-Unis
- Californie, Michigan, Minnesota, New Jersey, Ontario
- Tokyo, Toronto
- Université de Toronto
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Adenosine A2A receptor antagonist istradefylline (KW‐6002) reduces “off” time in Parkinson's disease: A double‐blind, randomized, multicenter clinical trial (6002‐US‐005)</title><author><name sortKey="Lewitt, Peter A" sort="Lewitt, Peter A" uniqKey="Lewitt P" first="Peter A." last="Lewitt">Peter A. Lewitt</name></author><author><name sortKey="Guttman, M" sort="Guttman, M" uniqKey="Guttman M" first="M." last="Guttman">M. Guttman</name></author><author><name sortKey="Tetrud, James W" sort="Tetrud, James W" uniqKey="Tetrud J" first="James W." last="Tetrud">James W. Tetrud</name></author><author><name sortKey="Tuite, Paul J" sort="Tuite, Paul J" uniqKey="Tuite P" first="Paul J." last="Tuite">Paul J. Tuite</name></author><author><name sortKey="Mori, Akihisa" sort="Mori, Akihisa" uniqKey="Mori A" first="Akihisa" last="Mori">Akihisa Mori</name></author><author><name sortKey="Chaikin, Philip" sort="Chaikin, Philip" uniqKey="Chaikin P" first="Philip" last="Chaikin">Philip Chaikin</name></author><author><name sortKey="Sussman, Neil M" sort="Sussman, Neil M" uniqKey="Sussman N" first="Neil M." last="Sussman">Neil M. Sussman</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:4C849F98158530925A8AC68C2925986ABA4BA92E</idno><date when="2008" year="2008">2008</date><idno type="doi">10.1002/ana.21315</idno><idno type="url">https://api.istex.fr/document/4C849F98158530925A8AC68C2925986ABA4BA92E/fulltext/pdf</idno><idno type="wicri:Area/Main/Corpus">000D62</idno><idno type="wicri:Area/Main/Curation">000C02</idno><idno type="wicri:Area/Main/Exploration">000E73</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Adenosine A2A receptor antagonist istradefylline (KW‐6002) reduces “off” time in Parkinson's disease: A double‐blind, randomized, multicenter clinical trial (6002‐US‐005)</title><author><name sortKey="Lewitt, Peter A" sort="Lewitt, Peter A" uniqKey="Lewitt P" first="Peter A." last="Lewitt">Peter A. Lewitt</name><affiliation><wicri:noCountry code="subField">Henry Ford Hospital</wicri:noCountry></affiliation><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><placeName><region type="state">Michigan</region></placeName><wicri:cityArea>Department of Neurology, Wayne State University School of Medicine, Detroit</wicri:cityArea></affiliation></author><author><name sortKey="Guttman, M" sort="Guttman, M" uniqKey="Guttman M" first="M." last="Guttman">M. Guttman</name><affiliation wicri:level="4"><country xml:lang="fr">Canada</country><wicri:regionArea>Division of Neurology, Department of Medicine, University of Toronto, Toronto, Ontario</wicri:regionArea><orgName type="university">Université de Toronto</orgName><placeName><settlement type="city">Toronto</settlement><region type="state">Ontario</region></placeName></affiliation></author><author><name sortKey="Tetrud, James W" sort="Tetrud, James W" uniqKey="Tetrud J" first="James W." last="Tetrud">James W. Tetrud</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><placeName><region type="state">Californie</region></placeName><wicri:cityArea>The Parkinson Institute, Sunnyvale</wicri:cityArea></affiliation></author><author><name sortKey="Tuite, Paul J" sort="Tuite, Paul J" uniqKey="Tuite P" first="Paul J." last="Tuite">Paul J. Tuite</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><placeName><region type="state">Minnesota</region></placeName><wicri:cityArea>Department of Neurology, University of Minnesota, Minneapolis</wicri:cityArea></affiliation></author><author><name sortKey="Mori, Akihisa" sort="Mori, Akihisa" uniqKey="Mori A" first="Akihisa" last="Mori">Akihisa Mori</name><affiliation wicri:level="3"><country xml:lang="fr">Japon</country><wicri:regionArea>Kyowa Hakko Kogyo Co., Ltd., Tokyo</wicri:regionArea><placeName><settlement type="city">Tokyo</settlement></placeName></affiliation></author><author><name sortKey="Chaikin, Philip" sort="Chaikin, Philip" uniqKey="Chaikin P" first="Philip" last="Chaikin">Philip Chaikin</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><placeName><region type="state">New Jersey</region></placeName><wicri:cityArea>Kyowa Pharmaceutical, Inc., Princeton</wicri:cityArea></affiliation></author><author><name sortKey="Sussman, Neil M" sort="Sussman, Neil M" uniqKey="Sussman N" first="Neil M." last="Sussman">Neil M. Sussman</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><placeName><region type="state">New Jersey</region></placeName><wicri:cityArea>Kyowa Pharmaceutical, Inc., Princeton</wicri:cityArea></affiliation></author></analytic><monogr></monogr><series><title level="j">Annals of Neurology</title><title level="j" type="abbrev">Ann Neurol.</title><idno type="ISSN">0364-5134</idno><idno type="eISSN">1531-8249</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2008-03">2008-03</date><biblScope unit="volume">63</biblScope><biblScope unit="issue">3</biblScope><biblScope unit="page" from="295">295</biblScope><biblScope unit="page" to="302">302</biblScope></imprint><idno type="ISSN">0364-5134</idno></series><idno type="istex">4C849F98158530925A8AC68C2925986ABA4BA92E</idno><idno type="DOI">10.1002/ana.21315</idno><idno type="ArticleID">ANA21315</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0364-5134</idno></seriesStmt></fileDesc><profileDesc><textClass></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Objective: Based on new understanding of nondopaminergic pathways involved in Parkinson's disease (PD) pathophysiology, a selective adenosine A2A receptor antagonist, istradefylline, shows promise for the treatment of PD. Methods: Istradefylline (40mg/day) was studied in levodopa‐treated PD subjects experiencing prominent wearing‐off motor fluctuations. At 23 North American sites, 196 subjects were randomized in a double‐blind, 12‐week outpatient clinical trial of istradefylline (114 completing the trial) or placebo (58 completing the trial). The primary efficacy measure was change from baseline to end point in the percentage of daily awake “off” time, recorded by subjects using a patient PD diary. Secondary end points evaluated “on” time (including “on time with dyskinesia”), the Unified Parkinson's Disease Rating Scale, and a Clinical Global Impression–Improvement of Illness score. Clinical laboratory, electrocardiograms, vital signs, and adverse event monitoring comprised the safety monitoring. Results: After randomization, approximately 88% of subjects completed the double‐blind period. Compared with baseline, the decrease of daily awake “off” time for istradefylline was a mean (± standard deviation) of −10.8 ± 16.6% (95% confidence interval, −13.46 to −7.52) and for placebo, −4.0 ± 15.7% (95% confidence interval, −7.73–0.31; p = 0.007 using two‐way analysis of variance). This effect corresponded to changes from baseline in total daily awake “off” time of −1.8 ± 2.8 hours for istradefylline and −0.6 ± 2.7 hours for placebo (p = 0.005). Treatment‐emergent adverse effects with istradefylline were generally mild. Interpretation: Istradefylline was safe, well tolerated, and offered a clinically meaningful reduction in “off” time without increased troublesome dyskinesia. Ann Neurol 2008</div></front></TEI><affiliations><list><country><li>Canada</li><li>Japon</li><li>États-Unis</li></country><region><li>Californie</li><li>Michigan</li><li>Minnesota</li><li>New Jersey</li><li>Ontario</li></region><settlement><li>Tokyo</li><li>Toronto</li></settlement><orgName><li>Université de Toronto</li></orgName></list><tree><country name="États-Unis"><region name="Michigan"><name sortKey="Lewitt, Peter A" sort="Lewitt, Peter A" uniqKey="Lewitt P" first="Peter A." last="Lewitt">Peter A. Lewitt</name></region><name sortKey="Chaikin, Philip" sort="Chaikin, Philip" uniqKey="Chaikin P" first="Philip" last="Chaikin">Philip Chaikin</name><name sortKey="Sussman, Neil M" sort="Sussman, Neil M" uniqKey="Sussman N" first="Neil M." last="Sussman">Neil M. Sussman</name><name sortKey="Tetrud, James W" sort="Tetrud, James W" uniqKey="Tetrud J" first="James W." last="Tetrud">James W. Tetrud</name><name sortKey="Tuite, Paul J" sort="Tuite, Paul J" uniqKey="Tuite P" first="Paul J." last="Tuite">Paul J. Tuite</name></country><country name="Canada"><region name="Ontario"><name sortKey="Guttman, M" sort="Guttman, M" uniqKey="Guttman M" first="M." last="Guttman">M. Guttman</name></region></country><country name="Japon"><noRegion><name sortKey="Mori, Akihisa" sort="Mori, Akihisa" uniqKey="Mori A" first="Akihisa" last="Mori">Akihisa Mori</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000E73 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000E73 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:4C849F98158530925A8AC68C2925986ABA4BA92E
|texte= Adenosine A2A receptor antagonist istradefylline (KW‐6002) reduces “off” time in Parkinson's disease: A double‐blind, randomized, multicenter clinical trial (6002‐US‐005)
}}
| This area was generated with Dilib version V0.6.23. |  |